Cost-benefit analysis of ALK diagnosis in patients with non-small cell lung cancer in Spain

被引：0

作者：

Ortega Granados, A. L. ^{[1
]}

Rojo Todo, F. ^{[2
]}

Alvarez Alvarez, R. ^{[3
]}

Majem Tarruella, M. ^{[4
]}

Ruiz de Alda Iparraguirre, L. ^{[5
]}

Garcia Verdes-Montenegro, J. F. ^{[6
]}

Gordo Flores, R. ^{[6
]}

Gonzalez-Dominguez, A. ^{[7
]}

Ivanova Markova, Y. ^{[7
]}

Sanchez San Cristobal, R. ^{[7
]}

机构：

[1] Complejo Hosp Jaen, Med Oncol, Jaen, Spain

[2] Hosp Univ Fdn Jimenez Diaz, Pathol Anat, Madrid, Spain

[3] Hosp Gregorio Maranon, Med Oncol, Madrid, Spain

[4] Hosp Santa Creu & Sant Pau, Med Oncol, Barcelona, Spain

[5] Roche, Corp Affairs, Madrid, Spain

[6] Roche, Dept Med, Madrid, Spain

[7] Weber, Pharmacoecon & Market Access, Madrid, Spain

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1809

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1204P

引用

页码：S960 / S960

页数：1

共 50 条

[1] Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain
Majem, Margarita
Alvarez, Rosa
Laura Ortega, Ana
Ruiz de Alda, Lucia
Gordo, Rocio
Francisco Garcia, J.
Ivanova-Markova, Yoana
Gonzalez-Dominguez, Almudena
Sanchez San Cristobal, Raquel
Rojo, Federico
GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2022, 9 : 82 - 90
[2] Cost-Benefit of Minimally Invasive Staging of Non-small Cell Lung Cancer A Decision Tree Sensitivity Analysis
Steinfort, Daniel P.
Liew, Danny
Conron, Matthew
Hutchinson, Anastasia F.
Irving, Louis B.
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1564 - 1570
[3] ALK rearrangement in non-small cell lung cancer
Naulleau, Gaspard
Birsen, Gary
Mansuet-Lupo, Audrey
Leroy, Karen
Wislez, Marie
BULLETIN DU CANCER, 2025, 112 (03) : 3S86 - 3S94
[4] ASSESSING THE HEALTHCARE COST OF DIABETIC NON-SMALL CELL LUNG CANCER PATIENTS COMPARED TO NON-SMALL CELL LUNG CANCER PATIENTS
Ruban, C.
Blanchette, C. M.
Howden, R.
Kowalkowski, M.
Marino, J.
Saunders, W.
VALUE IN HEALTH, 2017, 20 (09) : A428 - A428
[5] Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer
Johanna S. M. Mattsson
Hans Brunnström
Verena Jabs
Karolina Edlund
Karin Jirström
Stephanie Mindus
Linnéa la Fleur
Fredrik Pontén
Mats G. Karlsson
Christina Karlsson
Hirsh Koyi
Eva Brandén
Johan Botling
Gisela Helenius
Patrick Micke
Maria A. Svensson
BMC Cancer, 16
[6] Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer
Mattsson, Johanna S. M.
Brunnstrom, Hans
Jabs, Verena
Edlund, Karolina
Jirstrom, Karin
Mindus, Stephanie
la Fleur, Linnea
Ponten, Fredrik
Karlsson, Mats G.
Karlsson, Christina
Koyi, Hirsh
Branden, Eva
Botling, Johan
Helenius, Gisela
Micke, Patrick
Svensson, Maria A.
BMC CANCER, 2016, 16
[7] Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer
Shirish M. Gadgeel
Current Treatment Options in Oncology, 2017, 18
[8] Sequencing of ALK Inhibitors in ALK plus Non-Small Cell Lung Cancer
Gadgeel, Shirish M.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (06)
[9] Metformin enhances the benefit of ALK inhibitors in ALK translocation-positive non-small cell lung cancer cells
Kim, Mi Young
Kim, Geum Ock
Shin, Dong Hoon
Kim, Tae Min
Kim, Jin-Soo
CANCER RESEARCH, 2015, 75
[10] The landscape of ALK alterations in non-small cell lung cancer
Desai, A.
Mohammed, T.
Rakshit, S.
Krull, J.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S707 - S707

← 1 2 3 4 5 →